Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOUNTAINEER-03 first-line HER2-positive metastatic colorectal cancer study
jRCT2031220580Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of tucatinib, trastuzumab, oxaliplatin, levoleucovorin, fluorouracil and 2 more in colorectal cancer (CRC) and colorectal adenocarcinoma (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Jun 2023; status: recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on jRCT2031220580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220580.